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Available online 10 September 2016Extracellular vesicles (EVs) mediate normal physiological homeostasis and pathological processes by facilitating
intercellular communication. Research of EVs in basic science and clinical settings requires both methodological
standardization and development of reference materials (RM). Here, we show insights and results of biological
RM development for EV studies. We used a three-step approach to ﬁnd and develop a biological RM. First, a lit-
erature searchwas done to ﬁnd candidates for biological RMs. Second, a questionnairewas sent to EV researchers
querying the preferences for RM and their use. Third, a biological RMwas selected, developed, characterized, and
evaluated.
The responses to the survey demonstrated a clear and recognized need for RMoptimized for the calibration of EV
measurements. Based on the literature, naturally occurring and produced biological RM, such as virus particles
and liposomes, were proposed as RM. However, none of these candidate RMs have properties completely
matching those of EVs, such as size and refractive index distribution. Therefore, we evaluated the use of
nanoerythrosomes (NanoE), vesicles produced from erythrocytes, as a potential biological RM. The strength of
NanoE is their resemblance to EVs. Compared to the erythrocyte-derived EVs (eryEVs), NanoE have similar mor-
phology, a similar refractive index (1.37), larger diameter (70% of the NanoE are over 200 nm), and increased
positive staining for CD235a and lipids (Di-8-ANEPPS) (58% and 67% in NanoE vs. 21% and 45% in eryEVs,
respectively).
Altogether, our results highlight the general need to develop and validate new RMwith similar physical and bio-
chemical properties as EVs to standardize EV measurements between instruments and laboratories.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Quantiﬁcation1. Introduction
Extracellular vesicles (EVs) are lipid bilayer surrounded particles
that contain proteins, lipids, metabolites, and nucleic acids (Yanez-Mo
et al., 2015). EVs are produced by most cells, including bacteria and
plant cells, making cross-kingdom communication possible (Samuel et
al., 2015). EVs have active physiological and pathophysiological roles
and they are functional components of intercellular communication,
thereby offering possibilities in the development of therapy and diag-
nostics, or collectively, theranostics (Fais et al., 2016). EVs are often clas-
siﬁed into exosomes and microvesicles based on size and the route of
formation, but increasing data have revealed this to be an oversimpliﬁ-
cation, since the isolated populations are heterogeneous and have, 00014, University of Helsinki,
n).
. This is an open access article underoverlapping properties including size, density, and molecular markers
(van der Pol et al., 2016).
The molecular content and concentrations of EVs in human body
ﬂuids have raised increasing interest for their use as biomarkers (Fais
et al., 2016). A biomarker based on EVs has not yet been realized, partly
due to the lack of standardization. Standardization is difﬁcult because
the calibration of instruments, the interpretation and validation of re-
sults, and the comparison ofmeasurements require a referencematerial
(RM) with physical properties equal to EVs. One of the most analyzed
property of an EV sample is the concentration. However, the measured
EV concentration depends on the physical properties of EVs, such as the
size distribution and refractive index (RI), complicating the analysis, as
explained below.
EVs smaller than 300 nm constitute the majority of EV population
(Aatonen et al., 2014; Arraud et al., 2014; Dragovic et al., 2011, 2013;
Gercel-Taylor et al., 2012; Varga et al., 2014; Yoshioka et al., 2013).
Typical size distributions of EVs start at ~30 nm, show a peak at athe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Dependency of the different detection techniques on EV properties and EV sample
properties.
AFM DLS FCM NTA SAXS TEM TRPS
Adhesion + − − − − + −
Buoyancy − − − − − − ±
Charge − ± − ± − − +
Concentration + + + + ++ + +
Membrane proteins ± − ± ± − ± −
Monodispersity − ++ − ± ++ − −
Refractive index − + ++ + − − −
Size − + + + ++ − +
Spherical shape − ++ ++ + + − ++
Stiffness + − − − − + −
Abbreviations: AFM: atomic force microscopy; DLS: dynamic light scattering without
charge option; FCM: ﬂow cytometry; NTA: nanoparticle tracking analysis without charge
option; SAXS: small-angle X-ray scattering; TEM: transmission electron microscopy;
TRPS: tunable resistive pulse sensing.
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ponential function for diameters N100 nm (Fraikin et al., 2011; van
der Pol et al., 2016). With the exception of transmission electron mi-
croscopy (TEM), none of the current analytical methods are able to de-
tect the entire population of EVs (van der Pol et al., 2016). The inability
to detect the smallest EVs leads to both differences and underestimation
of the determined concentration. Consequently, the reported number of
EVs in normal humanplasma ranges from104 to 1012mL−1 (vander Pol
et al., 2014a). This 8 orders of magnitude difference in EV concentra-
tions emphasizes the need for standardization.
In ﬂow cytometry, which is one of the most commonly used
methods in EV studies (Lacroix et al., 2010), particle detection is often
based on light scattering. Because the RI of silica (1.45) and polystyrene
beads (1.61) is higher than the mean RI of naturally occurring EVs (~
1.39), applying a gate on the scatter signals of silica or polystyrene
beads will result in erroneous estimations of EV size and concentration
(van der Pol et al., 2012, 2014b). For example, a lower size gate set with
200 nm polystyrene beads, which scatter the same amount of light as
EVs of ~500 nm (Chandler et al., 2011), leads to the exclusion of EVs be-
tween 200 and 500 nm (van der Pol et al., 2014b). Since the concentra-
tion of EVs decreases with increasing diameter, a polystyrene size gate
generally leads to an underestimation of the actual EV concentration.
With nanoparticle tracking analysis (NTA) the Stokes–Einstein
equation is used to derive the hydrodynamic diameter of EVs from
their Brownian motion (Dragovic et al., 2011). Although in NTA, the RI
of EVs does not affect the measured diameter, the EV size distribution
and RI do affect the measured concentration (Filipe et al., 2010), be-
cause the measured concentration depends on the brightness of the
scattering particle.
Altogether, these examples emphasize the urgent need to develop
RM with a similar RI and size distribution, but preferably also with a
morphology (for TEM) and zeta potential (for tunable resistive pulse
sensing, TRPS) similar to the studied EVs. Ultimately, also other RM
properties wouldmatch those of EVs, including surfacemolecules or in-
ternal cargo. This is challenging because the development of an optimal
RM for EV studies and the analytical methods for their detection are de-
pendent on each other. Further, the different analytical techniques de-
pend on different properties of EVs (Table 1). In this study, we took a
three-step approach to develop RM for EV studies: a literature search
was performed to ﬁnd candidates for biological RM, and then EV re-
searchers were asked for the preferences for RM and their use. Finally,
we took a step forward and developed an erythrocyte-derived EV-RM,
nanoerythrosomes (NanoE), and evaluated its usability.2. Materials and Methods
2.1. Literature Search
The task of discovering a potential biological RM for EV studies was
initiated through discussions with various professionals of “Metrologi-
cal characterization of micro-vesicles from body ﬂuids” (METVES;
www.metves.eu) program. Based on the discussions, the initial catego-
ries of RM were determined and a literature search was conducted in
Google and PubMed using terms such as “erythrocyte ghost”, “RBC car-
rier”, “outer membrane vesicles”, “nanobacteria”, “viral particle”, “coc-
coid bacteria”, “liposome”, “cell organelle”, “stability”, production”,
and “preparation” to elaborate the properties of potential RM. Initial in-
clusion criteria for potential RM were submicron size and organic com-
position. To further investigate the beneﬁts of the selected RM, experts
from the EV ﬁeld were consulted regarding the properties of potential
RM from the literature search. Candidates were excluded if the particles
contained infection risk, did not express sufﬁcient physical and bio-
chemical resemblance to EVs, or were poorly storable. The literature
search and expert consultation was conducted from 10/2014 to 11/
2014.2.2. Survey of RM and Their Use in EV Studies
A questionnaire (Appendix 1) was designed to collect the following
information: methods in use for the characterization and quantiﬁcation
of EVs, current use of RM, desired andminimal physical and biochemical
requirements of RM, and opinions of other potential RM. The question-
nairewas sent to 14 stakeholders from theMETVES program and32 col-
laborators from the Laboratory of Experimental Clinical Chemistry
(Academic Medical Center, Amsterdam, Netherlands) working with
EVs. Replies were collected from 11/2014 to 12/2014.2.3. Preparation of RM from Erythrocyte Concentrates
Standard leukocyte-reduced erythrocyte concentrates were used to
produce NanoE. Outdated concentrates were obtained from Sanquin
(Amsterdam, The Netherlands) and the Finnish Red Cross Blood Service
(Helsinki, Finland). Concentrates were handled anonymously, and only
concentrates that could not be administered clinically were used as ac-
cepted by the Finnish Supervisory Authority for Welfare and Health
(Valvira, Finland).
To isolate erythrocyte-derived EVs (eryEVs), 25 mL of the concen-
trate was diluted with 25 mL of 0.22 μm ﬁltered calcium- and magne-
sium-free 1× phosphate-buffered saline (PBS [Sigma-Aldrich, St. Louis,
MO, USA]) and centrifuged for 20 min at 1560×g, room temperature
(RT)without brake (Centrifuge 5810R, Eppendorf, Hamburg, Germany)
(Varga et al., 2014). Supernatant was transferred to new tubes and cen-
trifuged 3 times under the same settings. The obtained supernatant was
centrifuged for 1 h in 100,000×g at 4 °C (Optima™MAX-XPUltracentri-
fuge with rotor TLA-55, k-factor 66, Beckman Coulter, Brea, CA, USA),
after which the pellet was washed with similar ultracentrifugation. Fi-
nally, the pellet was suspended with PBS to the initial volume and
aliquoted to 100-μL aliquots for storage at−70 °C (Fig. 1A).
NanoE production was initiated by separating the erythrocytes from
the concentrate: 25 mL of concentrate was diluted with 25 mL cold (+
4 °C) PBS and centrifuged at 300×g for 10 min at 4 °C without a brake
(Centrifuge 5810 R). The pellet was suspended to an equal volume of
cold PBS, centrifuged 1560×g for 20 min at 4 °C without a brake (Cen-
trifuge 5810 R). The washing was repeated 2 more times. Next, three
different disruption methods were evaluated to produce NanoE:
Freeze-thawing: 500 μL aliquots of erythrocytes were treated with 3
consecutive freeze–thaw cycles of 5 min in liquid nitrogen and 5 min
in 37 °C water bath.
N2 bomb treatment: 5mL of erythrocytes were diluted with 10mL of
PBS in 50 mL Falcon tube to facilitate nitrogen access to the cells. The
tubes were placed in N2 bomb (Parr Cell Disruption Bomb, Moline, IL,
USA). A pressure of 75 Psi was created using nitrogen and after
Fig. 1. A step-by-step protocol for harvesting EVs from erythrocyte concentrate (A) and schematic of the production of nanoerythrosomes (B).
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in a 50 mL Falcon tube.
Ultrasonication: 15 mL of erythrocytes were sonicated in an ice bath
with either Branson digital sonicator 250-D (Branson Ultrasonics, Dan-
bury, CT, USA) equipped with microtip using continuous sonication,
60% power and 30 or 45 s sonication, or Bandelin Sonopuls
ultrasonicator (BANDELIN electronic GmbH & Co. KG, Berlin, Germany)
equipped with MS73 microtip and 30 s continuous ultrasonication.
After disruption, the suspensions containing membrane fragments
were diluted with an equal volume of cold PBS, and centrifuged for
1560×g at 20 min and +4 °C without brake (Centrifuge 5810 R) to re-
move remaining cells and larger fragments. Remnants were washed by
transferring 500 μL aliquots of supernatant to Eppendorf tubes, diluting
the suspension 1:1 with cold PBS and centrifuging 10 min in 20,000×g
for 10 min and +4 °C without brake (Mikro 200R, Andreas Hettich
GmbH & Co. KG, Tuttlingen, Germany). Remnants were washed 3
times by suspending the pellet in 1 mL of cold PBS. The washed pellet
was suspended in 100 μL of +37 °C PBS and transferred into 10× vol-
ume of +37 °C PBS to allow the resealing process at +37 °C (water
bath) for 1 h. After the resealing process, the NanoE were aliquoted to
100 μL aliquots and stored in−70 °C.2.4. Transmission Electron Microscopy
Samples were ﬁxed 30 min in 0.1% (weight/volume, w/v) parafor-
maldehyde (Electron Microscopy Sciences, Hatﬁeld, PA). Next, a 200-
mesh EM copper grid with formvar coating (Electron Microscopy Sci-
ences) was placed on top of a sample (10 μL), and incubated for 7 min
at RT. The grids were transferred to 1.75% uranyl acetate (w/v) for neg-
ative staining. The grid was imaged using a Tecnai 12 transmission elec-
tron microscopy (TEM, FEI Company, Eindhoven, The Netherlands),
operated at 80 kV.2.5. Nanoparticle Tracking Analysis
The same NanoE samples were measured with the instruments
LM14C, NS300, and NS500 using the same settings (camera level 8, 3
videos of 90 s, 10,000-fold dilution). Analysis of the acquired videos
was performedwith threshold 5 and gain 10. The usedNTA instruments
and their speciﬁcations are listed in Table 2. LM14C was also used to
study how storage affects the size distribution and the concentration
of NanoE. NanoE samples were ﬁrst measured with NTA immediately
after preparation and then up to 10 weeks with biweekly measure-
ments (Supplementary Fig. 1).2.6. Flow Cytometry
NanoE and eryEVs were characterized using Apogee A50 micro
(Apogee Flow Systems, Hertfordshire, UK) equipped with a 405 nm
laser for measuring scatter and a 488 nm laser for measuring ﬂuores-
cence. Fluorescence light was spectrally ﬁltered by bandpass ﬁlters
(525/50, 575/30), and a long pass ﬁlter (650 nm). Particles were labeled
with a FITC-labeled anti-CD235a antibody (clone 11EB-7-6, Beckman
Coulter, Brea, CA, USA) and a lipid dye Di-8-ANEPPS (Invitrogen, Wal-
tham, MA, USA). For CD235a, the NanoE and eryEVs concentration
was ~108 mL−1 as determined by NTA (LM14C). The labeling volume
was 100 μL. Possible antibody aggregates were removed before use by
centrifuging for 5 min at 18,890×g and 20 °C without brakes, and
10 μL of the antibodywas used for each sample. After 30min incubation
in the dark, the labeling reaction was stopped by adding 900 μL of
0.22 μm ﬁltered PBS. IgG1-FITC was used as an isotype control (clone
MOPC-21, BD Pharmingen, San Jose, CA, USA). For the Di-8-ANEPPS la-
beling, 1 μL of 12.5× Di-8-ANEPPS lipid dye preparation (1 μL Di-8-
ANEPPS, 6.25 μL pluronic acid (product code#P3000MP [ThermoFisher,
Waltham, MA, USA)], and 5.25 μL mQwater) was added to 200 μL sam-
ples of eryEVs and NanoE at a concentration of ~107 mL−1. As free Di-8-
ANEPPS aggregates in the buffer, the amount of Di-8-ANEPPS-positive
particles in the buffer without EVs was deducted from samples in data
analysis. Samples were incubated for at least 30 min, RT, covered from
light. For sample detection, large-angle light scattering or small-angle
light scattering was used as a trigger and used voltages and thresholds
were 320 and 31 for large-angle light scattering and 295 and 14 for
small-angle light scattering, respectively. Samples were injected at
4.5 μL/min, datawas collected for 120 s for each sample and threewash-
ing cycles were performed between the samples. NanoE and eryEVs
were additionally compared to bead mixture of silica and polystyrene
beads (Apogee Flow Systems).
2.7. SDS-PAGE
The protein compositions of eryEV and NanoE samples were studied
by loading equal amounts of 0.3 μg of protein (determinedwith μBCAkit
[Thermo Fisher Scientiﬁc]) together with Multicolor broad range pro-
tein ladder (Thermo Fisher Scientiﬁc) to commercial Mini-Protean
TGX 10% gels (BioRad, Hercules, CA, USA). The gels were run with
180 V for 1 h in 1× Tris/glycine/SDS buffer (BioRad). The gelwas ﬁxated
(30% ethanol, 0.5% acetic acid [Merck, Kenilworth, NJ, USA]) for 1 h, after
which it was rinsed for 10min in 20% ethanol and 10min in water. The
gel was sensitized using freshly prepared sodium thiosulphate (0.02 g/
100 mL [Sigma-Aldrich]) for 1 min. The gel was rinsed twice in water
for 20 s and stained in freshly prepared silver nitrate (0.1 g/50 mL
Table 2
Speciﬁcations of the NTA instruments and software.
NTA
instrument Laser Camera
Software version in data
collection
Software version in data
analysis
LM14C Violet laser: 405 nm, 70 mW (Malvern Instruments
Ltd., Malvern, UK)
sCMOS camera (Hamamatsu Photonics K.K.,
Hamamatsu, Japan)
3.0 3.1
NS300 Violet laser: 405 nm, 65 mW (Malvern Instruments
Ltd.)
sCMOS camera (Hamamatsu Photonics K.K.) 3.1 3.1
NS500 Violet laser: 405 nm, 45 mW (Malvern Instruments
Ltd.)
EMCCD camera (Andor Technology, Tokyo,
Japan)
3.1 3.1
7S. Valkonen et al. / European Journal of Pharmaceutical Sciences 98 (2017) 4–16[Merck]) for 30 min. The gel was rinsed in water for 10 s, after which it
was developed using freshly prepared development solution (70 μL of
37% formaldehyde [Merck], 3 g of potassium carbonate [Sigma-Aldrich],
1 mg of sodium thiosulphate [Sigma-Aldrich], and added to 100 mL of
water) for 4 min. The development was stopped with incubation in
stopping solution (50 g/L Tris base [Merck], 2.5% acetic acid [Merck])
for 1 min, after which the gel was stored in water. The Western blots
were prepared as mentioned before (Aatonen et al., 2014).
2.8. Determination of Refractive Index
The RI of NanoE and eryEVs were determined by independently
measuring the diameter and the light scattering power of individual
particles with NTA and solving the inverse scattering problem with
Mie theory (van der Pol et al., 2014b).
2.9. Statistics
Statistical signiﬁcance was determined by using two-tailed t-test
(GraphPad Prism v.5.0.1.)
3. Results
3.1. Literature Search
Although several studies have characterized anddescribed the use of
monodisperse (Lacroix et al., 2010; Chandler et al., 2011; Maas et al.,
2015) and bimodal (Nicolet et al., 2016) synthetic RM, the reported
use of biological RM is limited (van der Pol et al., 2012; Anon., n.d.-a).
The following literature search describes potential, naturally occurring
or “produced” RM, which could be further developed for EV analyses.
3.1.1. Naturally Occurring Sources for Biological RM
Submicron particles with physical and biochemical properties simi-
lar to EVs can be isolated from naturally occurring sources. These may
include 1) isolated EV populations from, e.g. cell cultures, 2) plasma li-
poproteins, plant and marine viruses, and 3) small spherically shaped
(coccoid) bacteria, or picoplankton (Table 3).
(1) Potential EV sources are in vitro cell cultures (Lazaro-Ibanez et al.,
2014), cultures of Dictyostelium discoideum (Tatischeff et al.,
2012), therapeutic clinical grade erythrocyte (Varga et al.,
2014) and platelet (Black et al., 2015) concentrates, urine (van
der Pol et al., 2014a), and outer membrane vesicles produced
by bacteria (Biller et al., 2014). Here, the speciﬁc advantage is
that the obtained RM have enhanced physical and biochemical
similarities, including the molecular contents, with actual EVs.
These EV sources are also fairly accessible and safe. Thus, well-
characterized EVs would also be the perfect EV-RM candidates.
(2) Lipoproteins and viral particles from plant and marine sources
are suitable as EV-RMbecause they have a size distribution over-
lapping with the bulk of EVs (Aatonen et al., 2014; Arraud et al.,
2014; Dragovic et al., 2011; Dragovic et al., 2013; Gercel-Tayloret al., 2012; Varga et al., 2014; Yoshioka et al., 2013; Anon.,
n.d.-b, n.d.-c; Oster, 1950; van Antwerpen et al., 1999; Sawle et
al., 2002; McFarlane et al., 2005) and they do have a relatively
small variation in size (van Antwerpen et al., 1999; Sawle et al.,
2002; McFarlane et al., 2005; Salpeter and Zilversmit, 1968;
Colhoun et al., 2002). However, amajor drawback of lipoproteins
and viral particles is that the RI of these particles is higher than
the RI of EVs, due to their high protein content, a prominent
problem especially of protein-enveloped viruses. Another issue
of using viral particles is their biosafety, which could be
circumvented by producing virus-like particles, i.e. particles lack-
ing the viral genome. The mass production of virus-like particles
is possible in plant or insect cells (Machida and Imataka, 2015;
Santi et al., 2006).
(3) Another possible source of biological RM are non-pathogenic
bacteria and picophytoplankton, i.e. aquatic organisms of both
prokaryotic and eukaryotic origin ranging between 600 nm and
2000 nm in diameter (Anon., n.d.-d). Several non-pathogenic
marine bacteria and picophytoplankton strains exist (personal
communication with representatives of Roscoff Culture Collec-
tion; Roscoff, France) and can be purchased for culturing. The
beneﬁt of cultures of non-pathogenic bacteria and
picophytoplankton is that the cultures could be harnessed into
mass production to provide twopopulations of particleswith dif-
ferent size distributions. Bacteria can be used as larger particles
(N600 nm) and the corresponding bacteria-derived outer mem-
brane vesicles can be used as smaller particles (b250 nm) (Biller
et al., 2014). As outermembrane vesicles have comparable phys-
ical and biochemical properties as the bacteria (Biller et al.,
2014), the main difference would be their size. By maintaining
cultures, the biological RM would be essentially self-generating
with affordable and effortless maintenance depending of the
used strain. A literature search for non-pathogenic bacteria spe-
cies, which could be used as biological RM based on their size,
suggested several spherically shaped (coccoid) bacteria with re-
ported diameters of b1000 nm (Bae et al., 1972; Balkwill and
Casida, 1973; Barbier et al., 1999; Lai et al., 2000; Osburn and
Amend, 2011).3.1.2. Production of Biological RM
Besides harvesting EVs as RM from naturally occurring sources, sub-
micron particles with EV-like properties can be produced from various
sources. Here, we included particles produced only from biological ma-
terials including disrupted cells and different lipid constructs (Table 4).
Biological RM can be produced by disrupting cells to produce small
vesicles from the fragments yielding particles with varying diameters
(Marchesi and Palade, 1967; Heidrich and Leutner, 1974; Lin and
Macey, 1978; Yoon et al., 2015; Jo et al., 2014). The main advantage of
using such materials is that the physical and biochemical properties of
the obtained RM would better resemble EVs compared to synthetic
RM (Yoon et al., 2015; Jo et al., 2014). Erythrocytes are theoretically
Table 3
Naturally occurring potential biological reference materials (RM).
RM
Diameter
(nm)
Polydispersity
(CV) RI
Resemblance
to EVs Considerations References
EVs from
Cell lines 30–1000 N20% ~1.38 5 EVs stable for months when
stored−80 °C
Lazaro-Ibanez et al. (2014)
Dictyostelium discoideum 50–300 35%–70% – 5 – Tatischeff et al. (2012)
Erythrocyte or platelet
concentrates
10–350 N20% – 4/5 EVs stable for months when
stored−80 °C
Varga et al. (2014), Black et al. (2015)
Lyophilized exosomes* 30–100 N20% 1.37–1.39 5 Commercially available, can
be stored for months
Anon. (n.d.-e)
Outer membrane vesicles from
(marine) bacteria
10–350 – – 5 – Biller et al. (2014), Li et al. (1998), Kadurugamuwa
and Beveridge (1997), Schooling and Beveridge
(2006), Beveridge (1999)
Urine 45–500 35%–40% 1.37 5 EVs stable for months when
stored−80 °C
van der Pol et al. (2014a, 2014b), Tatischeff et al.
(2012)
Lipoproteins
High-density lipoproteins 6–15 ~5% 1.45−1.6 4 Must be stored under nitrogen
or argon, if stored in +4 °C.
Can be stored at−80 °C for
months
van der Pol et al. (2014b), van Antwerpen et al.
(1999), Sawle et al. (2002), McFarlane et al. (2005),
Salpeter and Zilversmit (1968), Colhoun et al.
(2002), Perusse et al. (2001), Wood et al. (2006)
Low-density lipoproteins 18–25 b10%
Intermediate-density
lipoproteins
30 ~1.5%
Very low-density lipoproteins 30–80 ~20%
Chylomicrons 200–600 N20%
Viral particles from
Marine virus species 110–130 b20% – 2 Can be stored for months in−
80 °C. No safety restrictions, if
particles do not contain
genomic material
Anon. (n.d.-d)
Plant virus species 20–85 b20% 1.52–1.57 2 van der Pol et al. (2014b), Anon. (n.d.-b, n.d.-c)
Oster (1950)
Coccoid-shaped organisms
Aquatic
bacteria/pico(phyto)plankton
300-1000 – 1.35-1.47** 5 Can be stored for months in−
80 °C. No safety restrictions, if
particles do not contain
genomic material.
Biller et al. (2014), Anon. (n.d.-d), Lai et al. (2000),
Ackleson and Spinrad (1988), Spinrad and Brown
(1986), Kuo et al. (2014), Hashemi et al. (2011)
Nanobacteria from soil 200–1000 – – 5 Bae et al. (1972), Balkwill and Casida (1973)
RMwere categorized according to size, polydispersity, refractive index (RI), and the resemblance to the EVs. Resemblance to EVswas scored on 1–5 points depending onwhether the RM
has (1) no resemblance, (2) proteins and genomic material but no lipid membrane, (3) phospholipid membrane, (4) phospholipid membrane containing proteins, or (5) phospholipid
membrane containing proteins and genomicmaterial. *= Exosomes fromHansaBiomed, Tallinn, Estonia. **=Values based on the references and the refractive index ofwater at 488 nm.
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characterized and they are devoid of intracellular membranes
(Virtanen et al., 1998). Additionally, erythrocytes are structurally stableTable 4
Produced biological reference materials (RM). RM were categorized according to size, polydisp
RM
Diameter
(nm) Polydispersity (CV) RI
Disrupted
Preparation method A b200 N20% –
Preparation method B 200–700 N20% –
Preparation method C 100–5000 N20% –
Preparation method D 100–300 20%–35% –
Preparation method E 100 – –
Lipid cons
Liposomes 100 ~5% 1.363–1.392
Liposomes (commercially
available*)
100 and
500
b20% for smaller
particles,
N20% for bigger
particles
Varies with used
buffer
Lipoparticles** 191 13% –
Oil droplets*** b100 b20% Engineered to
preferred RI
Resemblance to EVs was scored from 1 to 5 points depending on whether the RM has (1) no r
membrane, (4) phospholipid membrane containing proteins, or (5) phospholipid membrane c
lands; ** = lipoparticles from Integral Molecular, Philadelphia, PA, USA; *** = oil from Apogeeduring extended storage (Chaplin, 1982) and are an easily accessible
material. For these reasons, erythrocytes from clinical surplus concen-
trates were used to produce an RM for testing and evaluation. Differentersity, refractive index (RI), and the resemblance to the EVs.
Resemblance to
EVs Considerations References
cells
4 – Marchesi and Palade (1967)
4 – Heidrich and Leutner (1974)
4 – Lin and Macey (1978)
5 – Yoon et al. (2015)
5 – Jo et al. (2014)
tructs
3 – Lapinski et al. (2007), Matsuzaki et
al. (2000)
3-5 Can be stored at least 12
months
Anon., (n.d.-f)
3-4 Can be stored for 18
months
Anon. (n.d.-g)
1 Can be stored at least 12
months
Anon. (n.d.-h, n.d.-i),
esemblance, (2) proteins and genomic material but no lipid membrane, (3) phospholipid
ontaining proteins and genomic material. * = Liposomes from Excytex, Zeist, The Nether-
Flow Systems, Hertfordshire, UK or Cargille Laboratories, Cedar Grove, NJ, USA.
9S. Valkonen et al. / European Journal of Pharmaceutical Sciences 98 (2017) 4–16methods for erythrocyte disruption were compared, and a method for
NanoE production was developed (Fig. 1B). An additional advantage of
using erythrocytes is that they can be used to produce two types of bio-
logical RM for comparison: 1) by disrupting the erythrocytes NanoE are
formed, and 2) by harvesting the spontaneously shed eryEVs.
Biological RM can also be obtained from lipid constructs such as lipo-
somes that are extensively used as delivery vehicles (Allen and Cullis,
2004; van der Meel et al., 2014) and their production methods are
well known. Liposomes of a desired size can be prepared by
ultrasonication or extrusion of the starting material through polycar-
bonate ﬁlters of a set pore size (Lapinski et al., 2007; Akbarzadeh et
al., 2013). As the liposomes are produced from bulkmaterial, their com-
position is well characterized. Especially, liposomes with a small diam-
eter (~70 nm) prepared by extrusion have b20% variation in size (CV,
ratio of the standard deviation to the mean, expressed as percentage)
(Garcia-Diez et al., 2016). An advantage of liposomes is that their RI
can be manipulated during the production (Fenzl et al., 2015). Another
type of RM resembling liposomes are non-infectious virus-like particles
called lipoparticles, which consist of a lipid membrane constructed on
top of a protein core. These lipoparticles have a well-deﬁned diameter
of ~190 nm with a narrow size distribution (CV = 13%), and they areFig. 2. Results from 46 EV laboratories based on a questionnaire asking (A) which techniques w
properties for optimal RM; (D) minimal requirements for a RM; and (E) willingness to use pla
www.metves.eu), reproduced with permission. NTA = nanoparticle tracking analysis; PCR =stable during storage. On request, additional proteins could be attached
to the lipoparticle surface, whichwill increase their biochemical similar-
ity to EVs.
Finally, as a non-biological exception, we include oil droplets as one
option of a produced RM because they would offer close similarity with
EVs regarding the size and RI. As with liposomes, extrusion can be used
to prepare oil droplets of a speciﬁc size from oils of commercial pro-
viders. The advantage of using oil droplets is that the RI can be designed
exactly, thus improving their resemblance to EVs (personal communi-
cation with Oliver Kenyon, CEO of Apogee Flow Systems, Hertfordshire,
UK and representatives of Cargille Laboratories, Cedar Grove, NJ, USA).
3.2. Survey
The literature search revealed several different types of RM, which
had varying beneﬁts and drawbacks. Therefore, the opinions of labora-
tories working with EVs were surveyed through a questionnaire to dis-
cover the requirements of biological RM by the end-users. A
questionnaire (Appendix 1) was sent to 46 laboratories and the re-
sponse rate was 44%. Flow cytometry was indicated as the most com-
mon method for EV studies (90% of the responders; Fig. 2A),ere in use for EV studies (multiple choices allowed); (B) currently used RM; (C) preferred
nt viruses/marine bacteria as RM. Values represent mean ± S.D. Published previously (in
polymerase chain reaction.
Fig. 3. Representative transmission electron microscope micrographs of erythrocytes
disrupted by three consecutive freeze–thaw cycles (A and B), by an N2 bomb (C and D),
by a 30-s ultrasonication (E and F), and by a 45-s ultrasonication (G and H).
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EVs. Besides using functional assays (50%), dynamic light scattering/
NTA (35%), electron microscopy (25%), and Western blotting (25%)
were listed as the most commonly used techniques for EV studies (Fig.
2A). When laboratories were asked whether they have used an RM in
their studies, the majority reported using synthetic RM (58%), 5% used
biological RM, and 16% used both. However, 20% used no RM in their
EV studies (Fig. 2B).
The laboratories were asked to rank the order of importance regard-
ing the desired properties, i.e. the biochemical composition,
monodispersity, price, refractive index, and safety. The biochemical
composition (average rank of 4.33/6) and stability (average rank of
4.25/6) were indicated as the most important properties (Fig. 2C).
Next, price, RI, and safety were listed with an almost equal importance
(average ranks of 3.13/6, 3.21/6, and 3.20/6, respectively), whilst
monodispersity was considered as the least important property (aver-
age rank of 2.90/6) (Fig. 2C). Regarding the requirements for the struc-
tural properties, 50% of the laboratories working with EVs would be
satisﬁed if the RM would contain a phospholipid membrane, 30%
would additionally require proteins, and 20%would require a phospho-
lipidmembrane and the presence of both proteins and genomicmateri-
al (Fig. 2D). Finally, 60% would be willing to use plant viruses and
marine bacteria as RM, provided that their biosafety can be assured
(Fig. 2E).
3.3. NanoE Production
NanoE were selected as a biological RM candidate, based on the lit-
erature review and the survey responses. Three erythrocyte disruption
methods (freeze–thaw cycles, N2 bomb, and ultrasonication) were test-
ed in the NanoE production. Freeze–thaw cycles did not break down the
erythrocytes sufﬁciently, as seen in TEM micrographs (Fig. 3A), al-
though the treatment made the erythrocytes leaky, resulting in white
erythrocyte ghosts. Furthermore, the number of submicron particles
was almost non-existent (Fig. 3B). Disruption using an N2 bomb result-
ed in either intact or completely shattered erythrocytes (Fig. 3C), and
similar to the freeze–thaw treatment, submicron particles were almost
non-existent (Fig. 3D). Finally, ultrasonication disrupted erythrocytes
almost completely (Fig. 3E), producing a concentration of submicron
particles higher than the application of freeze–thaw cycles or an N2
bomb (Fig. 3F). Despite using different ultrasonicators, the size distribu-
tion proﬁle of the produced NanoE was similar (data not shown). Ex-
tending the length of the ultrasonication treatment from 30 s to 45 s
decreased the ﬁnal particle concentrationwithout affecting the size dis-
tribution (Fig. 3G and H). Based on the results, an additional washing
step was included in the ﬁnal protocol to remove any remaining intact
cells and larger cell fragments, seen especially in freeze–thaw cycle
and N2 bomb disruptions.
3.4. EryEVs vs. NanoE
To examine the usability of NanoE as RM, their physical and bio-
chemical properties were compared with the naturally occurring
eryEVs from the same concentrate. The morphology of eryEVs and
NanoE was similar as inspected by TEM (Fig. 4A and B). Also, the RI dis-
tribution and mean RI (1.37) measured by NTA were similar for eryEVs
andNanoE (Fig. 4C). The protein content of NanoEwas considerably dif-
ferent from eryEVs as shown by SDS-PAGE (Fig. 4D). Enriched proteins
inWestern blotting of NanoE vs. eryEVswere, e.g. hemoglobin and Band
3 (data not shown). The size of NanoE was slightly greater than that of
eryEVs: 66% of the NanoE population was larger than 200 nm, and the
main population (58%) was between 200 and 400 nm, whereas only
b30% of eryEVs were larger than 200 nm when determined by NTA
(Fig. 4E). The difference in size distribution was also observed in ﬂow
cytometry, where a majority of NanoE were found in the same area as
180 nm silica beads in contrast to the smaller eryEVs (Fig. 4F).Next, ﬂow cytometry was used to determine the fraction of Di-8-
ANEPPS positivity and CD235a antigen density of eryEVs and NanoE.
Lipid labeling of NanoE by Di-8-ANEPPS showed a higher percentage
of labeled particles compared to the eryEVs (67% vs. 45% respectively,
p b 0.05, Fig. 5). Similarly, the CD235a labeling was signiﬁcantly higher
for NanoE than for eryEVs (58% vs. 21%, respectively, p b 0.0001, Fig. 6,
ﬂuorescence intensity 68.3 ± 21.6 vs. 40.5 ± 13.0).
3.5. Application of NanoE as a Biological RM to Standardize EV
Measurements
To demonstrate the relevance of using a biological RM for the stan-
dardization of EV measurements, NanoE was analyzed using three dif-
ferent NTA instruments. The same batch of NanoE was measured
using the same settings optimized for the LM14C instrument, which
were then applied during measurements with NTA models NS300 and
NS500. The size distribution of the detected particles was similar
Fig. 4. Comparison of erythrocyte-derived EV (eryEVs) and nanoerythrosomes (NanoE) showing transmission electron microscopy micrographs from (A) eryEVs and (B) NanoE; (C)
refractive index measurements; (D) silver-stained SDS-PAGE gel of NanoE and eryEV samples; (E) size distribution measured by nanoparticle tracking analysis; and (F) polystyrene
and silica bead mixture, unlabeled eryEVs, and unlabeled NanoE as detected with ﬂow cytometer. Gate 1 = 180 nm silica beads; gate 2 = 240 nm silica beads; gate 3 = 300 nm silica
beads; gate 4 = 590 nm silica beads; gate 5 = 800 nm silica beads; gate 6 = 1300 nm silica beads; gate 7 = (ﬂuorescent) 110 nm polystyrene beads; gate 8 = (ﬂuorescent) 500 nm
polystyrene beads. Values represent mean ± S.D., n= 3 (C) or 18–20 (E).
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ranging from 200 to 400 nm in diameter (Fig. 7A). However, although
the same NanoE concentrations were expected to be measured, the ob-
tained NanoE concentrations varied ~40-fold among the different in-
struments (Fig. 7B).
4. Discussion and Conclusions
The development of RM for EVs is tightly intertwined with the de-
velopment of the EV analysis methods as both feed each other's ad-
vancement. Although progress has been made with different sizes of
monodisperse nanoparticles (van der Pol et al., 2014b; Wang et al.,2008), the analyses of complex mixtures of polydisperse particles are
challenging (van der Pol et al., 2016). The EuropeanMetrology Research
Program has initiated important standardizationwork in anticipation of
the rapid momentum of the EV research ﬁeld and therefore funded
METVES, a program focused on metrological characterization of EVs
from body ﬂuids. In collaboration with METVES, this study was per-
formed by a national EV research platform funded as an initiative of a
Finnish industry- and university-driven research program SalWe-GID,
throughwhichmultiple end-users are interested in the EV standardiza-
tion for their improved utilization. The progress inMETVES on synthetic
RMand the applicablemethods for their analysis encouraged us to try to
foresee the further needs for biological EV-resembling RM. In order to
Fig. 5. (A) Apogee A50 dot plots showing the Di-8-ANEPPS labeling of erythrocyte-derived EVs (eryEVs) and nanoerythrosomes (NanoE) compared to negative controls; (B) datagram
showing the Di-8-ANEPPS labeling of eryEVs and NanoE compared to negative control; and (C) comparison of Di-8-ANEPPS labeling of eryEVs and NanoE. Values represent mean ±
S.D., n= 6, * = p b 0.05.
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ﬂow cytometry and synthetic RMwere indicated as themost used com-
bination in EV studies, which underpins the problems of RM develop-
ment. Especially with the ﬂow cytometers, the use of synthetic RM
leads to the selection of particles within the size range of cells (van
der Pol et al., 2012; Chandler et al., 2011), thereby affecting the conclu-
sions of EV studies particularly from clinical samples such as plasma.
Biochemical resemblance to EVs and stability were the most crucial
properties for a biological RM according to the laboratories who partic-
ipated in the survey. As more unusual sources, e.g. plant viruses or ma-
rine bacteria, were also acceptable as RM, a wide range of possibilities
worth investigating were listed from the literature, if they matched
the basic criteria set for RM.
Based on previous results (Anon., n.d.-a), the survey, and the litera-
ture review, NanoE was chosen for further development and evaluation
as a candidate for biological RM. The optimized method of NanoE pro-
duction required ultrasonication to disrupt erythrocytes, a method pre-
viously used to produce submicron particles from lipids (Lapinski et al.,
2007). Upon resealing, the produced particles resembled eryEVs regard-
ing their morphology and RI. The larger size and the enhanced CD235a/
Di-8-ANEPPS labeling of NanoE vs. that of eryEVs may be beneﬁcial for
their use as EV-RM. Thus, NanoE represents a reasonable option to EV-
dedicated ﬂow cytometers and possibly also to earlier models of ﬂow
cytometers, which are able to detect 300–700 nm single particles with
EV-like RI (van der Pol et al., 2012). The enhanced CD235a positivity
may be explained by the instantaneous disruption of erythrocytes,
where no selection of surface proteins occurs compared to natural EV
budding (Dragovic et al., 2013). This was also supported by the differ-
ences of the total protein composition of NanoE and EryEVs. A drawback
of NanoEmay thus be that since they do not expose common EV surface
markers such as CD9, CD63, or CD81 (Yoshioka et al., 2013; Andreu and
Yanez-Mo, 2014) nor signiﬁcant amounts of genomicmaterial, theywill
not be applicable as RM for methods using these properties as the basisof the analysis. However, the lack of typical EV markers and expression
of erythrocyte-speciﬁcmarker CD235awould enable spiking of EV sam-
ples with NanoE, which might be useful in the quantiﬁcation of EVs
from different sources. As such, NanoE can already be utilized as an
RM for NTA, TRPS, and ﬂow cytometry.
Comparing the properties of NanoE with those indicated by the sur-
vey, NanoE have a matching RI and contain phospholipid membrane
and proteins; criteriawhich fulﬁl the needs of themajority of the partic-
ipating EV laboratories. Furthermore, NanoE are relatively stable, safe,
and cheap to produce in large quantities from surplus clinical grade
erythrocyte concentrates. Although theNanoE population cannot be de-
scribed as monodisperse, out of the desired properties, monodispersity
was ranked as the least important. Monodispersity could be substantial-
ly improved by additional preparative steps, thereby allowing the isola-
tion of populations with a narrow size range using different ﬁltration
(Zinsser and Tang, 1927), chromatographic (Boing et al., 2014),
microﬂuidics (Ashcroft et al., 2012; Lee et al., 2015), or ﬁeld-ﬂow frac-
tionation (Petersen et al., 2014; Agarwal et al., 2015)methods. Provided
that a monodisperse biological RM could be produced in the future, fur-
ther characterization by methods such as small-angle X-ray scattering
could be, at least hypothetically, used to generate “traceable measure-
ments”, i.e. measurements that could ultimately be related to the SI
unit (in this case “metre”) through an unbroken chain of comparisons
with knownuncertainties (Varga et al., 2014).More realistically, the fol-
lowing step in the development of similarly equivalent standards with
NanoEwould be themechanical disruption of platelets or cells from im-
mortalized cell cultures to produce biological RM that would better re-
semble multiple EV properties, including EV surface markers and
internal cargo, and could then be utilized by multiple analytical
approaches.
To demonstrate the relevance of biological RM for the standardiza-
tion of EV measurements, we measured the same batch of NanoE
using the same settings on different NTA instruments. The size
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NanoE concentrations varied ~40-fold among the NTA instruments,
which emphasizes the importance of using an EV-RM. The particle con-
centration measured by NTA is assumed to be proportional to the mean
number of scattering particles in the ﬁeld-of-view of the microscope,
whichdepends on the intensity andwavelength of the illumination, col-
lection angles of the objective, the sensitivity of the camera with theFig. 6. (A) Apogee A50 dot plots showing CD235a-labeling of erythrocyte-derived EVs (eryEVs)
NanoE; and (C) comparison of CD235a-labeling of eryEVs and NanoE. Values represent mean ±applied settings (Maas et al., 2015; Gardiner et al., 2013), the analysis
software, and the brightness of the scattering particles, which in turn
depends on the particle size, refractive index, and concentration (due
to multiple and dependent scattering). The differences in the particle
concentrations obtained with similar NTA instruments are caused by
an inappropriate calibration factor between the mean number of scat-
tering particles in the ﬁeld-of-view and the provided concentrationand nanoerythrosomes (NanoE); (B) a datagram showing CD235a-labeling of eryEVs and
S.D., n= 6, *** = p b 0.0001.
Fig. 8. Optimal properties for a biological reference material for EV studies.
Fig. 7. Characterization of the applicability of the nanoerythrosome standard by
measuring the same standard with Nanoparticle Tracking Analysis models LM14C,
NS300, and NS500 by (A) particle concentrations and (B) size distribution. Values
represent mean ± S.D., n= 5.
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Once the concentration of the NanoE can be measured in a traceable
way, NanoE can be used to calibrate NTA instruments, i.e. relating the
mean number of scattering particles in the ﬁeld-of-view of NTA to the
traceably measured concentration, and deﬁning the smallest detectable
EV diameter. In analogy to NTA, other instruments can be calibrated
with NanoE to improve themeasurement quality within each laborato-
ry. Despite the challenges, EV quantiﬁcation by particle enumeration is,
in most cases, a more accurate way of comparing samples than any in-
direct EV quantiﬁcation method such as determination of protein con-
tent. The protein content of an EV sample may be independent of the
particle number and can vary with the cell activation (Aatonen et al.,
2014), the used cell line (Lazaro-Ibanez et al., 2014), and the method
bywhich the protein content ismeasured (Okutucu et al., 2007). There-
fore, direct particle measurements should be favoured in the case of EV
quantiﬁcation and the expressed concentration should be coupled with
the knowledge of the detection limits of the instruments/method.
A summary of the optimal properties of a biological RM is presented
in Fig. 8, based on the collected information gathered during this study.
However, although desirable, it is unlikely that one biological RMwould
be applicable, not to mention optimal, for all different measurement
techniques due to the vast variation in the detection methods (Table
1). Therefore, the search for an optimal biological RM should be
approached from a technical perspective, research focus, and consider-
ing the EV material. Still, the development of such materials will not be
easy.
As the research on EVs progresses, and the use of EVs is pursued in
clinical assays and for theranostics, it is crucial to develop various RM
to enable precise and reproducible measurements. This will most likely
beﬁrst achieved by the use of synthetic RM in ﬂow cytometry and in the
techniques for EV enumeration. However, the simultaneous develop-
ment of biological RM would clearly provide additional beneﬁts to the
ﬁeld. Where synthetic RM could be useful for instrument calibration,biological RM could be used for validation of EV measurements. By
spreading the RM for common use, the repeatability of studies and the
reliability of datawill be increased,which in turnwill increase the trans-
parency of EV research and improve standardization. Since the discov-
ery of new biological RM for EV studies is a laborious task, it requires
the united work of all laboratories and openness. Research networks
such as the MEHAD (Extracellular Vesicles in Health and Disease,
COST Action BM 1202) and metrological initiatives such as those con-
ducted by METVES, are in a crucial position to take this endeavor to
the next level, but ultimately, it is the interest and responsibility of all
EV researchers to make this possible.
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PBS phosphate-buffered saline
RI refractive index
RM reference material
TEM transmission electron microscopy
TRPS tunable resistive pulse sensing
Acknowledgements
Part of this work was funded by SalWe Research Program Personal-
ized Diagnostics and Care (GET IT DONE) (Tekes—the Finnish Funding
Agency for Technology and Innovation grant Dnro 3986/31/2013 (SV,
MYP, SL, PS).
Part of this work was funded by the European Metrology Research
Programme (EMRP) under the Joint Research Project HLT02 (www.
metves.eu). The EMRP is jointly funded by the EMRP participating coun-
tries within the European Association of National Metrology Institutes
and the European Union (SV, YY and RN).
Part of this work was funded by Academy of Finland program grant
no. 287089 (PS, SV).
A. Grootemaat and N. Hajji (Laboratory of Experimental Clinical
Chemistry, Academic Medical Centre, Amsterdam, The Netherlands)
have contributed substantially to the article by performing TEMmicro-
graph processing and data collection.
15S. Valkonen et al. / European Journal of Pharmaceutical Sciences 98 (2017) 4–16Wewould like to thank L. Sankkila (Finnish Red Cross Blood Service,
Helsinki, Finland) for the excellent assistance with SDS-PAGE gels.
We acknowledge the kind help of the researchers who participated
in the survey.
The authors wish to acknowledge EU H2020 COST Action European
Network in Microvesicles and Exosomes in Health and Disease
[BM1202].
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ejps.2016.09.008.
References
Aatonen, M.T., Ohman, T., Nyman, T.A., Laitinen, S., Gronholm, M., Siljander, P.R., Aug 6
2014. Isolation and characterization of platelet-derived extracellular vesicles.
J. Extracell Vesicles 3. http://dx.doi.org/10.3402/jev.v3.24692 (eCollection 2014).
Ackleson, S.G., Spinrad, R.W., 1988 Apr 1. Size and refractive index of individual marine
participates: a ﬂow cytometric approach. Appl. Opt. 27 (7), 1270–1277.
Agarwal, K., Saji, M., Lazaroff, S.M., Palmer, A.F., Ringel, M.D., Paulaitis, M.E., 2015 May 19.
Analysis of exosome release as a cellular response to MAPK pathway inhibition. Lang-
muir 31 (19), 5440–5448.
Akbarzadeh, A., Rezaei-Sadabady, R., Davaran, S., Joo, S.W., Zarghami, N., Hanifehpour, Y.,
et al., 2013 Feb 22. Liposome: classiﬁcation, preparation, and applications. Nanoscale
Res. Lett. 8 (1), 102 (-276X-8-102).
Allen, T.M., Cullis, P.R., 2004Mar 19. Drug delivery systems: entering themainstream. Sci-
ence 303 (5665), 1818–1822.
Andreu, Z., Yanez-Mo, M., 2014 Sep 16. Tetraspanins in extracellular vesicle formation
and function. Front. Immunol. 5, 442.
Anon., d. Available at: http://www.metves.eu/downloads/reports/METVES_Report_Yuana_
2015_Biological_microvesicles%20_reference_materials.pdf (Accessed 4/25, 2016).
Anon., d. Online plant virus databaseAvailable at: http://pvo.bio-mirror.cn (Accessed 10/
22, 2014).
Anon., d. Online plant virus databaseAvailable at: http://www.dpvweb.net/index.php
(Accessed 10/25, 2014).
Anon., d. Available at: http://roscoff-culture-collection.org (Accessed 10/26, 2014).
Anon., d. Available at: http://www.hansabiomed.eu (Accessed 10/11, 2014).
Anon., d. Available at: http://www.excytex.com (Accessed 4/20, 2016).
Anon., d. Available at: http://www.integralmolecular.com (Accessed 4/20, 2016).
Anon., d. Available at: http://www.cargille.com (Accessed 4/20, 2016).
Anon., d. Available at: http://www.apogeeﬂow.com (Accessed 4/20, 2016).
Arraud, N., Linares, R., Tan, S., Gounou, C., Pasquet, J.M., Mornet, S., et al., 2014 May. Extra-
cellular vesicles from blood plasma: determination of their morphology, size, pheno-
type and concentration. J. Thromb. Haemost. 12 (5), 614–627.
Ashcroft, B.A., de Sonneville, J., Yuana, Y., Osanto, S., Bertina, R., Kuil, M.E., et al., 2012 Aug.
Determination of the size distribution of blood microparticles directly in plasma
using atomic force microscopy and microﬂuidics. Biomed. Microdevices 14 (4),
641–649.
Bae, H.C., Cota-Robles, E.H., Casida, L.E., 1972 Mar. Microﬂora of soil as viewed by trans-
mission electron microscopy. Appl. Microbiol. 23 (3), 637–648.
Balkwill, D.L., Casida Jr., L.E., 1973 Jun. Microﬂora of soil as viewed by freeze-etching.
J. Bacteriol. 114 (3), 1319–1327.
Barbier, G., Godfroy, A., Meunier, J.R., Querellou, J., Cambon, M.A., Lesongeur, F., et al., Oct
1999. Pyrococcus glycovorans sp. nov., a hyperthermophilic archaeon isolated from
the East Paciﬁc Rise. Int. J. Syst. Bacteriol. 49 (Pt 4), 1829–1837.
Beveridge, T.J., 1999 Aug. Structures of gram-negative cell walls and their derived mem-
brane vesicles. J. Bacteriol. 181 (16), 4725–4733.
Biller, S.J., Schubotz, F., Roggensack, S.E., Thompson, A.W., Summons, R.E., Chisholm, S.W.,
2014 Jan 10. Bacterial vesicles in marine ecosystems. Science 343 (6167), 183–186.
Black, A., Pienimaeki-Roemer, A., Kenyon, O., Orso, E., Schmitz, G., 2015 Sep. Platelet-de-
rived extracellular vesicles in platelet pheresis concentrates as a quality control ap-
proach. Transfusion 55 (9), 2184–2196.
Boing, A.N., van der Pol, E., Grootemaat, A.E., Coumans, F.A., Sturk, A., Nieuwland, R., 2014
Sep 8. Single-step isolation of extracellular vesicles by size-exclusion chromatogra-
phy. J. Extracell Vesicles 3. http://dx.doi.org/10.3402/jev.v3.23430 (eCollection 2014).
Chandler, W.L., Yeung, W., Tait, J.F., 2011 Jun. A new microparticle size calibration stan-
dard for use in measuring smaller microparticles using a new ﬂow cytometer.
J. Thromb. Haemost. 9 (6), 1216–1224.
Chaplin Jr., H., 1982 Jun. The proper use of previously frozen red blood cells for transfu-
sion. Blood 59 (6), 1118–1120.
Colhoun, H.M., Otvos, J.D., Rubens, M.B., Taskinen, M.R., Underwood, S.R., Fuller, J.H., 2002
Jun. Lipoprotein subclasses and particle sizes and their relationship with coronary ar-
tery calciﬁcation in men and women with and without type 1 diabetes. Diabetes 51
(6), 1949–1956.
Dragovic, R.A., Gardiner, C., Brooks, A.S., Tannetta, D.S., Ferguson, D.J., Hole, P., et al., 2011
Dec. Sizing and phenotyping of cellular vesicles using nanoparticle tracking analysis.
Nanomedicine 7 (6), 780–788.
Dragovic, R.A., Southcombe, J.H., Tannetta, D.S., Redman, C.W., Sargent, I.L., 2013 Dec 26.
Multicolor ﬂow cytometry and nanoparticle tracking analysis of extracellular vesicles
in the plasma of normal pregnant and pre-eclamptic women. Biol. Reprod. 89 (6), 151.Fais, S., O'Driscoll, L., Borras, F.E., Buzas, E., Camussi, G., Cappello, F., et al., 2016 Apr 26. Ev-
idence-based clinical use of nanoscale extracellular vesicles in nanomedicine. ACS
Nano 10 (4), 3886–3899.
Fenzl, C., Hirsch, T., Baeumner, A.J., 2015 11/03. Liposomes with high refractive index
encapsulants as tunable signal ampliﬁcation tools in surface plasmon resonance spec-
troscopy. Anal. Chem. 87 (21), 11157–11163 (2015).
Filipe, V., Hawe, A., Jiskoot, W., 2010 May. Critical evaluation of nanoparticle tracking
analysis (NTA) by NanoSight for the measurement of nanoparticles and protein ag-
gregates. Pharm. Res. 27 (5), 796–810.
Fraikin, J.L., Teesalu, T., McKenney, C.M., Ruoslahti, E., Cleland, A.N., 2011 May. A high-
throughput label-free nanoparticle analyser. Nat. Nanotechnol. 6 (5), 308–313.
Garcia-Diez, R., Gollwitzer, C., Krumrey, M., Varga, Z., 2016 Jan 26. Size determination of a
liposomal drug by small-angle X-ray scattering using continuous contrast variation.
Langmuir 32 (3), 772–778.
Gardiner, C., Ferreira, Y.J., Dragovic, R.A., Redman, C.W., Sargent, I.L., 2013 Feb 15. Extracel-
lular vesicle sizing and enumeration by nanoparticle tracking analysis. J. Extracell
Vesicles 2. http://dx.doi.org/10.3402/jev.v2i0.19671 (eCollection 2013).
Gercel-Taylor, C., Atay, S., Tullis, R.H., Kesimer, M., Taylor, D.D., 2012 Sep 1. Nanoparticle
analysis of circulating cell-derived vesicles in ovarian cancer patients. Anal. Biochem.
428 (1), 44–53.
Hashemi, N., Erickson, J.S., Golden, J.P., Jackson, K.M., Ligler, F.S., 2011 Jul 15. Microﬂow
cytometer for optical analysis of phytoplankton. Biosens. Bioelectron. 26 (11),
4263–4269.
Heidrich, H.G., Leutner, G., 1974 Jan 3. Two types of vesicles from the erythrocyte-ghost
membrane differing in surface charge. Separation and characterization by preparative
free-ﬂow electrophoresis. Eur. J. Biochem. 41 (1), 37–43.
Jo, W., Kim, J., Yoon, J., Jeong, D., Cho, S., Jeong, H., et al., 2014 Oct 21. Large-scale genera-
tion of cell-derived nanovesicles. Nanoscale 6 (20), 12056–12064.
Kadurugamuwa, J.L., Beveridge, T.J., 1997 Nov. Natural release of virulence factors in
membrane vesicles by Pseudomonas aeruginosa and the effect of aminoglycoside an-
tibiotics on their release. J. Antimicrob. Chemother. 40 (5), 615–621.
Kuo, J., Tew, K.S., Ye, Y.X., Cheng, J.O., Meng, P.J., Glover, D.C., 2014. Picoplankton dynamics
and picoeukaryote diversity in a hyper-eutrophic subtropical lagoon. J. Environ. Sci.
Health A Tox. Hazard. Subst. Environ. Eng. 49 (1), 116–124.
Lacroix, R., Robert, S., Poncelet, P., Kasthuri, R.S., Key, N.S., Dignat-George, F., et al., 2010
Nov. Standardization of platelet-derived microparticle enumeration by ﬂow cytome-
try with calibrated beads: results of the International Society on Thrombosis and
Haemostasis SSC Collaborative workshop. J. Thromb. Haemost. 8 (11), 2571–2574.
Lai, M.C., Shu, C.M., Chen, S.C., Lai, L.J., Chiou, M.S., Hua, J.J., 2000 Jul. Methanosarcina
mazei strain O1M9704, methanogen with novel tubule isolated from estuarine envi-
ronment. Curr. Microbiol. 41 (1), 15–20.
Lapinski, M.M., Castro-Forero, A., Greiner, A.J., Ofoli, R.Y., Blanchard, G.J., 2007 Nov 6. Com-
parison of liposomes formed by sonication and extrusion: rotational and translational
diffusion of an embedded chromophore. Langmuir 23 (23), 11677–11683.
Lazaro-Ibanez, E., Sanz-Garcia, A., Visakorpi, T., Escobedo-Lucea, C., Siljander, P., Ayuso-
Sacido, A., et al., 2014 Oct. Different gDNA content in the subpopulations of prostate
cancer extracellular vesicles: apoptotic bodies, microvesicles, and exosomes. Prostate
74 (14), 1379–1390.
Lee, K., Shao, H., Weissleder, R., Lee, H., 2015 Mar 24. Acoustic puriﬁcation of extracellular
microvesicles. ACS Nano 9 (3), 2321–2327.
Li, Z., Clarke, A.J., Beveridge, T.J., 1998 Oct. Gram-negative bacteria produce membrane
vesicles which are capable of killing other bacteria. J. Bacteriol. 180 (20), 5478–5483.
Lin, G.S., Macey, R.I., 1978 Sep 22. Shape and stability changes in human erythrocyte
membranes induced by metal cations. Biochim. Biophys. Acta 512 (2), 270–283.
Maas, S.L., de Vrij, J., van der Vlist, E.J., Geragousian, B., van Bloois, L., Mastrobattista, E., et al.,
2015 Feb 28. Possibilities and limitations of current technologies for quantiﬁcation of
biological extracellular vesicles and synthetic mimics. J. Control. Release 200, 87–96.
Machida, K., Imataka, H., 2015 Apr. Production methods for viral particles. Biotechnol.
Lett. 37 (4), 753–760.
Marchesi, V.T., Palade, G.E., 1967 Nov. The localization of Mg–Na–K-activated adenosine
triphosphatase on red cell ghost membranes. J. Cell Biol. 35 (2), 385–404.
Matsuzaki, K., Murase, O., Sugishita, K., Yoneyama, S., Akada, K., Ueha, M., et al., 2000 Jul
31. Optical characterization of liposomes by right angle light scattering and turbidity
measurement. Biochim. Biophys. Acta 1467 (1), 219–226.
McFarlane, C., Young, I.S., Hare, L., Mahon, G., McEneny, J., 2005Mar. A rapid methodology
for the isolation of intermediate-density lipoprotein: characterization of lipid compo-
sition and apoprotein content. Clin. Chim. Acta 353 (1-2), 117–125.
Nicolet, A., Meli, F., Evd, P., Yuana, Y., Gollwitzer, C., Krumrey, M., et al., 2016. Inter-labo-
ratory comparison on the size and stability of monodisperse and bimodal synthetic
reference particles for standardization of extracellular vesicle measurements. Meas.
Sci. Technol. 27 (3), 035701.
Okutucu, B., Dincer, A., Habib, O., Zihnioglu, F., 2007 Aug 1. Comparison of ﬁve methods
for determination of total plasma protein concentration. J. Biochem. Biophys.
Methods 70 (5), 709–711.
Osburn, M.R., Amend, J.P., 2011 Jan. Thermogladius shockii gen. nov., sp. nov., a hyperther-
mophilic crenarchaeote from Yellowstone National Park, USA. Arch. Microbiol. 193
(1), 45–52.
Oster, G., 1950May 20. Two-phase formation in solutions of tobaccomosaic virus and the
problem of long-range forces. J. Gen. Physiol. 33 (5), 445–473.
Perusse, M., Pascot, A., Despres, J.P., Couillard, C., Lamarche, B., 2001 Aug. A new method
for HDL particle sizing by polyacrylamide gradient gel electrophoresis using whole
plasma. J. Lipid Res. 42 (8), 1331–1334.
Petersen, K.E., Manangon, E., Hood, J.L.,Wickline, S.A., Fernandez, D.P., Johnson,W.P., et al.,
2014 Dec. A review of exosome separation techniques and characterization of B16-
F10 mouse melanoma exosomes with AF4-UV-MALS-DLS-TEM. Anal. Bioanal.
Chem. 406 (30), 7855–7866.
16 S. Valkonen et al. / European Journal of Pharmaceutical Sciences 98 (2017) 4–16Salpeter, M.M., Zilversmit, D.B., 1968 Mar. The surface coat of chylomicrons: electron mi-
croscopy. J. Lipid Res. 9 (2), 187–192.
Samuel, M., Bleackley, M., Anderson, M., Mathivanan, S., 2015 Sep 23. Extracellular vesi-
cles including exosomes in cross kingdom regulation: a viewpoint from plant–fungal
interactions. Front. Plant Sci. 6, 766.
Santi, L., Huang, Z., Mason, H., 2006 Sep. Virus-like particles production in green plants.
Methods 40 (1), 66–76.
Sawle, A., Higgins, M.K., Olivant, M.P., Higgins, J.A., 2002 Feb. A rapid single-step centrifu-
gation method for determination of HDL, LDL, and VLDL cholesterol, and TG, and
identiﬁcation of predominant LDL subclass. J. Lipid Res. 43 (2), 335–343.
Schooling, S.R., Beveridge, T.J., 2006 Aug. Membrane vesicles: an overlooked component
of the matrices of bioﬁlms. J. Bacteriol. 188 (16), 5945–5957.
Spinrad, R.W., Brown, J.F., 1986 Jun 15. Relative real refractive index of marine microor-
ganisms: a technique for ﬂow cytometric estimation. Appl. Opt. 25 (12), 1930.
Tatischeff, I., Larquet, E., Falcon-Perez, J.M., Turpin, P.Y., Kruglik, S.G., 2012 Nov 21. Fast
characterisation of cell-derived extracellular vesicles by nanoparticles tracking analy-
sis, cryo-electron microscopy, and Raman tweezers microspectroscopy. J. Extracell
Vesicles 1. http://dx.doi.org/10.3402/jev.v1i0.19179 (eCollection 2012).
van Antwerpen, R., La Belle, M., Navratilova, E., Krauss, R.M., 1999 Oct. Structural hetero-
geneity of apoB-containing serum lipoproteins visualized using cryo-electronmicros-
copy. J. Lipid Res. 40 (10), 1827–1836.
van der Meel, R., Fens, M.H., Vader, P., van Solinge, W.W., Eniola-Adefeso, O., Schiffelers,
R.M., 2014 Dec 10. Extracellular vesicles as drug delivery systems: lessons from the
liposome ﬁeld. J. Control. Release 195, 72–85.
van der Pol, E., van Gemert, M.J., Sturk, A., Nieuwland, R., van Leeuwen, T.G., 2012 May.
Single vs. swarm detection of microparticles and exosomes by ﬂow cytometry.
J. Thromb. Haemost. 10 (5), 919–930.
van der Pol, E., Coumans, F.A., Grootemaat, A.E., Gardiner, C., Sargent, I.L., Harrison, P., et
al., 2014 May 13a. Particle size distribution of exosomes and microvesicles deter-
mined by transmission electron microscopy, ﬂow cytometry, nanoparticle tracking
analysis, and resistive pulse sensing. J. Thromb. Haemost.van der Pol, E., Coumans, F.A., Sturk, A., Nieuwland, R., van Leeuwen, T.G., 2014 Oct 2b. Re-
fractive index determination of nanoparticles in suspension using nanoparticle track-
ing analysis. Nano Lett.
van der Pol, E., Boing, A.N., Gool, E.L., Nieuwland, R., 2016 Jan. Recent developments in the
nomenclature, presence, isolation, detection and clinical impact of extracellular vesi-
cles. J. Thromb. Haemost. 14 (1), 48–56.
Varga, Z., Yuana, Y., Grootemaat, A.E., van der Pol, E., Gollwitzer, C., Krumrey, M., et al.,
2014 Feb 4. Towards traceable size determination of extracellular vesicles.
J. Extracell Vesicles 3. http://dx.doi.org/10.3402/jev.v3.23298 (eCollection 2014).
Virtanen, J.A., Cheng, K.H., Somerharju, P., 1998 Apr 28. Phospholipid composition of the
mammalian red cell membrane can be rationalized by a superlattice model. Proc.
Natl. Acad. Sci. U. S. A. 95 (9), 4964–4969.
Wang, L., Zhao, W., Tan, W., 2008. Bioconjugated silica nanoparticles: development and
applications. Nano Res. 1 (2), 99–115.
Wood, R.J., Volek, J.S., Liu, Y., Shachter, N.S., Contois, J.H., Fernandez, M.L., 2006 Feb. Carbo-
hydrate restriction alters lipoprotein metabolism by modifying VLDL, LDL, and HDL
subfraction distribution and size in overweight men. J. Nutr. 136 (2), 384–389.
Yanez-Mo, M., Siljander, P.R., Andreu, Z., Zavec, A.B., Borras, F.E., Buzas, E.I., et al., 2015
May 14. Biological properties of extracellular vesicles and their physiological func-
tions. J. Extracell Vesicles 4, 27066.
Yoon, J., Jo, W., Jeong, D., Kim, J., Jeong, H., Park, J., 2015 Aug. Generation of nanovesicles
with sliced cellular membrane fragments for exogenous material delivery. Biomate-
rials 59, 12–20.
Yoshioka, Y., Konishi, Y., Kosaka, N., Katsuda, T., Kato, T., Ochiya, T., 2013 Jun 18. Compar-
ative marker analysis of extracellular vesicles in different human cancer types.
J. Extracell. Vesicles 2. http://dx.doi.org/10.3402/jev.v2i0.20424 (eCollection 2013).
Zinsser, H., Tang, F.F., 1927 Jul 31. Studies in ultraﬁltration. J. Exp. Med. 46 (2), 357–378.
